G40
Conditions
Interventions
Group 1: Following written study information and the provision of informed consent by the legal guardians, as well as assent from the child or adolescent, eligibility will be assessed according to the
Sponsors
Universitätsklinikum Bonn, Zentrum für Kinder- und Jugendmedizin, Abteilung für Neuropädiatrie & SPZ
Eligibility
Sex/Gender
All
Age
6 Years to 17 Years
Inclusion criteria
Inclusion criteria: - Healthy children and adolescents (normative sample) or children and adolescents with epilepsy (clinical validation sample) - Attendance at a mainstream school - Written informed consent from a parent or legal guardian - Age-appropriate assent from the child or adolescent
Exclusion criteria
Exclusion criteria: - Known epilepsy (for participants in the normative sample) - Known neurological disorders or chronic medical conditions involving the central nervous system - Known intellectual disability (IQ < 70 and/or special educational needs related to intellectual development) - Inability to cooperate sufficiently or to complete the assessment, as determined by the investigator - Insufficient German language proficiency that would interfere with understanding the test instructions, as determined by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome Measure: The primary outcome is performance on the newly implemented memory subtests (verbal and figural memory) as well as on the existing EpiTrack Junior subtests, for the purpose of deriving age-adjusted normative values and an age-adjusted total score for the extended EpiTrack Junior. Time point(s) of evaluation: At baseline (single assessment at study participation). Method of assessment: Scores will be obtained through standardized administration of the EpiTrack Junior, including the two newly developed memory subtests, in an individual testing session. Raw scores will be recorded and used to derive age-corrected normative scores and the overall test score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcome: Differences in the age-adjusted total score of the extended EpiTrack Junior and memory performance between the clinical validation sample (children and adolescents with epilepsy) and the normative sample. In addition, the discriminative validity of the extended EpiTrack Junior (e.g., using ROC analyses), test–retest reliability, practice effects, and reliable change indices will be evaluated. Time point(s) of evaluation: At baseline (normative and clinical validation samples) and approximately three months after the initial assessment for participants included in the retest sample. Method of assessment: Data will be collected through standardized administration of the extended EpiTrack Junior, including the newly implemented memory subtests. Clinical variables of the epilepsy sample will additionally be obtained from medical records. Analyses will include group comparisons, ROC analyses, and test–retest analyses. | — |
Countries
Germany
Contacts
Public ContactAlexandra Klotz
Universitätsklinikum Bonn, Zentrum für Kinder- und Jugendmedizin, Abteilung für Neuropädiatrie & SPZ
Outcome results
None listed